Very good post. It mirrors what I have been thinki
Post# of 5066
Posted On: 09/27/2013 11:16:06 AM
Re: BigCheezie #3401
Very good post. It mirrors what I have been thinking...
"You then have to find someone who will be able to run the pre-clinicals in an effective manner to satisfy the FDA requirements. Why not your own CSO?"
This is what I find most perplexing about the PR since Dr. Ichim is still presently the CSO of the company and this is his specialty. Not Dr. Min's. That is not to say that Dr. Min is not more than qualified for he very much is. But, this is Dr. Ichim's baby so-to-speak. So I am rather confused by this. Not to mention some timing and data issues that seem to contradict what has already been established. So it seemed anyway. Yes, still scratching my head...
Regarding Christopher Mizer, without putting myself at risk because I am bound by an NDA for the next eleven months, his separation from the company was due to let's say, a proposition that was most disagreeable to the company. I did not confirm this with Koos and my confidence in this being a legitimate claim is very high. There was no foul play on the part of the company with respect to Mizer's departure. Of that I am certain. At this juncture, that is all I can say about it, though.
"You then have to find someone who will be able to run the pre-clinicals in an effective manner to satisfy the FDA requirements. Why not your own CSO?"
This is what I find most perplexing about the PR since Dr. Ichim is still presently the CSO of the company and this is his specialty. Not Dr. Min's. That is not to say that Dr. Min is not more than qualified for he very much is. But, this is Dr. Ichim's baby so-to-speak. So I am rather confused by this. Not to mention some timing and data issues that seem to contradict what has already been established. So it seemed anyway. Yes, still scratching my head...
Regarding Christopher Mizer, without putting myself at risk because I am bound by an NDA for the next eleven months, his separation from the company was due to let's say, a proposition that was most disagreeable to the company. I did not confirm this with Koos and my confidence in this being a legitimate claim is very high. There was no foul play on the part of the company with respect to Mizer's departure. Of that I am certain. At this juncture, that is all I can say about it, though.
(0)
(0)RIVULET MEDIA INC. (RIVU) Stock Research Links
Scroll down for more posts ▼